<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571802</url>
  </required_header>
  <id_info>
    <org_study_id>LSGSIMVASTATIN</org_study_id>
    <nct_id>NCT03571802</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Simvastatin Post Laparoscopic Sleeve Gastrectomy (LSG)</brief_title>
  <official_title>The Need of Dosing Adjustment for Simvastatin in Obese Patients Post Bariatric Surgery- Laparoscopic Sleeve Gastrectomy (LSG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the change in systemic exposure of simvastatin post LSG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Morbid obesity (Body mass index &gt; 40 kg/m2 or 35-39 kg/m2 with comorbidity; 37.5 kg/m2 for
      Asians) is a growing global health issue. Bariatric surgery is the only intervention that has
      demonstrated sustainable reduction in weight and comorbidities.1,2 Among the various
      bariatric procedures, laparoscopic sleeve gastrectomy (LSG) has rapidly gained popularity
      worldwide.3,4 Physiological alterations following LSG include reduction in gastrointestinal
      surface and reduced retention of food. Bioavailability of drugs may be affected but published
      literature in this area is sparse and studies are usually small and uncontrolled.5-7
      Moreover, some reports concerning gastric banding and jejunoileal bypass are no longer
      practiced because of the associated risk. In general, bioavailability of orally administered
      drug changes with a reduction in gastrointestinal area. While Kroll et al showed slight
      increase in area under curve of rivaroxaban post bariatric surgery8, Skottheim et al
      demonstrated significant but variable change in systemic exposure of atorvastatin after
      gastric bypass (from threefold decrease to twofold increase) that diminished but was
      sustained with time (21-45 months post gastric bypass)9-10.

      No study has investigated the change in pharmacokinetics of simvastatin post LSG.

      Simvastatin is a widely-used lipid-lowering agent with a low bioavailability of 5% due to the
      extensive first pass metabolism.11 As simvastatin undergoes hydrolysis in the stomach to the
      active form12, it is postulated that bioavailability of simvastatin will decrease after
      LSG.13-15 A decrease in bioavailability may be associated with reduced efficacy. Authors of
      review articles suggested choosing an alternative agent to simvastatin post bariatric
      surgery. However, such recommendation is largely based on theoretical concern rather than
      solid evidence.14,15 A previous study attempted to model the pharmacokinetics of simvastatin
      post Roux-en-Y and biliopancreatic diversion with duodenal switch.13 The data is not
      applicable to LSG and the model did not take into account of the pH-dependent hydrolysis.
      This will be the first study aiming to investigate the change in systemic exposure of
      simvastatin post LSG.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pharmacokinetic parameters of simvastatin before and after laparoscopic sleeve gastrectomy will be compared in 10 patients. Each patient will serve as their own control for comparison.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC) of simvastatin</measure>
    <time_frame>baseline (before surgery). 3 months after surgery</time_frame>
    <description>Ratio of AUC of simvastatin for each subject before and 3 months after surgery will be calculated, the mean ratio will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax) of simvastatin</measure>
    <time_frame>baseline (before surgery). 3 months after surgery</time_frame>
    <description>Ratio of Cmax of simvastatin for each subject before and 3 months after surgery will be calculated, the mean ratio will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time at which maximum serum concentration (Tmax) of simvastatin</measure>
    <time_frame>baseline (before surgery). 3 months after surgery</time_frame>
    <description>Ratio of Tmax of simvastatin for each subject before and 3 months after surgery will be calculated, the mean ratio will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC) of simvastatin acid</measure>
    <time_frame>baseline (before surgery). 3 months after surgery</time_frame>
    <description>Ratio of AUC of simvastatin acid for each subject before and 3 months after surgery will be calculated, the mean ratio will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax) of simvastatin acid</measure>
    <time_frame>baseline (before surgery). 3 months after surgery</time_frame>
    <description>Ratio of Cmax of simvastatin acid for each subject before and 3 months after surgery will be calculated, the mean ratio will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time at which maximum serum concentration (Tmax) of simvastatin acid</measure>
    <time_frame>baseline (before surgery). 3 months after surgery</time_frame>
    <description>Ratio of Tmax of simvastatin acid for each subject before and 3 months after surgery will be calculated, the mean ratio will be reported</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Obesity</condition>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>simvastatin 20mg once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.
There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery.</description>
    <arm_group_label>intervention arm</arm_group_label>
    <other_name>Study arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned for laparoscopic sleeve gastrectomy at National University Hospital

          -  Taking statin

          -  Aged 21 or above

        Exclusion Criteria:

          -  Patient on concomitant treatment with medications/ food/ herbal supplements that may
             affect the pharmacokinetics of simvastatin: boceprevir, conivaptan, cyclosporine,
             efavirenz, mitotane, tocilizumab, rifamycin, amiodarone, amlodipine, aprepitant,
             azithromycin, colchicine, fenofibrate, imatinib, raltegravir, ranolazine,
             teriflunomide, ticagrelor, fusidic acid, protease inhibitors, telaprevir,
             telithromycin, gemfibrozil, erythromycin, clarithromycin, carbamazepine, rifampicin,
             ketoconazole, fluconazole, itraconazole, voriconanzole, diltiazem, verapamil,
             dexamethasone, prednisolone, phenytoin, ritonavir, indinavir, nelfinavir, bosentan,
             telithromycin, nefazodone, St John's wort, orlistat, sibutramine and other strong CYP
             3A4 inhibitors/ inducers

          -  Pregnant ladies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asim Shabbir, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asim Shabbir, MBBS</last_name>
    <phone>+65 9820 0814</phone>
    <email>cfsasim@nuhs.edu.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elaine Lo, PharmD</last_name>
    <phone>+65 9877 2682</phone>
    <email>elaine_lo@nuhs.edu.sg</email>
  </overall_contact_backup>
  <link>
    <url>https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13243</url>
    <description>Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery</description>
  </link>
  <reference>
    <citation>Skottheim IB, Stormark K, Christensen H, Jakobsen GS, Hjelmesaeth J, Jenssen T, Reubsaet JL, Sandbu R, Asberg A. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther. 2009 Sep;86(3):311-8. doi: 10.1038/clpt.2009.82. Epub 2009 Jun 3.</citation>
    <PMID>19494810</PMID>
  </reference>
  <reference>
    <citation>Jakobsen GS, Skottheim IB, Sandbu R, Christensen H, Røislien J, Asberg A, Hjelmesæth J. Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin. Surg Endosc. 2013 Jun;27(6):2094-101. doi: 10.1007/s00464-012-2716-3. Epub 2012 Dec 18.</citation>
    <PMID>23247745</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>simvastatin</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>laparoscopic sleeve gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share IPD</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03571802/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

